Relapsing-remitting Multiple Sclerosis (RRMS)
Neurology
10
Pipeline Programs
6
Companies
7
Clinical Trials
1 recruiting
3
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
5
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
4100%
+ 4 programs with unclassified modality
On Market (3)
Approved therapies currently available
Competitive Landscape
5 companies ranked by most advanced pipeline stage
BiogenCAMBRIDGE, MA
4 programs1
2
peginterferon beta-1aPhase 41 trial
peginterferon beta-1aPhase 41 trial
DaclizumabPhase 3Monoclonal Antibody
NatalizumabN/AMonoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Biogenpeginterferon beta-1a
Biogenpeginterferon beta-1a
AmgenOcrelizumab
AbbVieDaclizumab
Novartisfingolimod
Immunic TherapeuticsIMU-838
BiogenNatalizumab
Clinical Trials (7)
Total enrollment: 2,060 patients across 7 trials
Plegridy Satisfaction Study in Participants
Start: Feb 2016Est. completion: Dec 2017193 patients
Phase 4Completed
Brimonidine Tartrate for the Treatment of Injection Related Erythema
Start: Feb 2016Est. completion: Aug 20160
Phase 4Withdrawn
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Start: Jan 2025Est. completion: Dec 2027444 patients
Phase 3Recruiting
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Start: Apr 2017Est. completion: Sep 201841 patients
Phase 3Terminated
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Start: Aug 2012Est. completion: Apr 20181,064 patients
Phase 3Terminated
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
Start: Jan 2019Est. completion: Dec 2029
Phase 2Active Not Recruiting
A Study for Tysabri Participant Preference
Start: Oct 2021Est. completion: Apr 2024318 patients
N/ACompleted
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
8h ago
Director of Finance
CoMind
London, UK
8h ago
Electronics Engineering Manager
CoMind
London, UK
8h ago
Director of Information Technology
Zavation Medical Products
9h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,060 patients
Monoclonal Antibody is the dominant modality (100% of programs)
6 companies competing in this space